Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + vincristine + doxorubicin + dexamethasone + pegaspargase + methotrexate + cytarabine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intrathecal, Oral
01
Overview
A multi-agent chemotherapy regimen combining seven drugs with complementary mechanisms used in hematologic malignancies. It includes the alkylating agent cyclophosphamide, the microtubule inhibitor vincristine, the anthracycline topoisomerase II inhibitor doxorubicin, the glucocorticoid dexamethasone, the long-acting asparagine-depleting enzyme pegaspargase, and the antimetabolites methotrexate and cytarabine. Together, these agents target DNA synthesis and repair, mitosis, amino acid availability, and lymphoid proliferation. Such combinations are used in acute lymphoblastic leukemia and certain lymphomas; exact dosing, scheduling, and CNS-directed administration (e.g., intrathecal methotrexate or cytarabine) vary by protocol.
- Other names
- cyclophosphamide + vincristine + doxorubicin + dexamethasone + pegaspargase + methotrexate + cytarabine regimen
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)DNA polymerase familyGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + vincristine + doxorubicin + dexamethasone + pegaspargase + methotrexate + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + vincristine + doxorubicin + dexamethasone + pegaspargase + methotrexate + cytarabine.